The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma

被引：0
|
作者：
Thai H Ho
Xian-De Liu
Yanqing Huang
Carla L Warneke
Marcella M Johnson
Anh Hoang
Pheroze Tamboli
Fen Wang
Eric Jonasch
机构：
[1] Mayo Clinic,Division of Hematology and Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Department of Genitourinary Medical Oncology
[3] Center for Cancer and Stem Cell Biology,Department of Biostatistics
[4] Texas A&M Institute of Biosciences and Technology,Department of Pathology
[5] The University of Texas MD Anderson Cancer Center,undefined
[6] The University of Texas MD Anderson Cancer Center,undefined
来源：
BMC Cancer | / 15卷
关键词：
FGF; Renal cell carcinoma; VEGF; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
    Ho, Thai H.
    Liu, Xian-De
    Huang, Yanqing
    Warneke, Carla L.
    Johnson, Marcella M.
    Hoang, Anh
    Tamboli, Pheroze
    Wang, Fen
    Jonasch, Eric
    BMC CANCER, 2015, 15
  • [2] Fibroblast growth factor receptor 1 (FGFR1) tyrosine phosphorylation regulates binding of FGFR substrate 2α (FRS2α) but not FRS2β to the receptor
    Zhang, Yongyou
    McKeehan, Kerstin
    Lin, Yongshun
    Zhang, Jue
    Wang, Fen
    MOLECULAR ENDOCRINOLOGY, 2008, 22 (01) : 167 - 175
  • [3] Ureteric Morphogenesis Requires Fgfr1 and Fgfr2/Frs2α Signaling in the Metanephric Mesenchyme
    Sims-Lucas, Sunder
    Di Giovanni, Valeria
    Schaefer, Caitlin
    Cusack, Brian
    Eswarakumar, Veraragavan P.
    Bates, Carlton M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (04): : 607 - 617
  • [4] Context-specific requirements for Fgfr1 signaling through Frs2 and Frs3 during mouse development
    Hoch, RV
    Soriano, P
    DEVELOPMENT, 2006, 133 (04): : 663 - 673
  • [5] The Activation of FGFR1/FRS2 Pathway and the Interaction with EGFR Pathway in Low-Grade Osteosarcoma
    Peng, Ran
    Xie, You
    Jing, Wenyi
    Qiu, Yan
    He, Xin
    Lu, Yang
    Zhang, Hongying
    LABORATORY INVESTIGATION, 2024, 104 (03) : S70 - S71
  • [6] Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using FGFR1 Inhibitors
    Goeke, F.
    Franzen, A.
    Menon, R.
    Goltz, D.
    Scheble, V.
    Kirsten, R.
    Vogel, W.
    Boehm, D.
    Schroeck, A.
    Perner, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S195 - S195
  • [7] Rationale for treatment of metastatic squamous cell carcinoma of the lung using FGFR1 Inhibitors
    Goeke, F.
    Franzen, A.
    Schroeck, A.
    Scheble, V.
    Kirsten, R.
    Menon, R.
    Goltz, D.
    Boehm, D.
    Vogel, W.
    Perner, S.
    VIRCHOWS ARCHIV, 2012, 461 : S51 - S51
  • [8] Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using FGFR1 Inhibitors
    Goeke, F.
    Franzen, A.
    Mennon, R.
    Scheble, V.
    Goltz, D.
    Kirsten, R.
    Boehm, D.
    Vogel, W.
    Schroeck, A.
    Perner, S.
    MODERN PATHOLOGY, 2012, 25 : 477A - 477A
  • [9] Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using FGFR1 Inhibitors
    Goeke, F.
    Franzen, A.
    Mennon, R.
    Scheble, V.
    Goltz, D.
    Kirsten, R.
    Boehm, D.
    Vogel, W.
    Schroeck, A.
    Perner, S.
    LABORATORY INVESTIGATION, 2012, 92 : 477A - 477A
  • [10] Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
    Hu, Mengdie
    Zhang, Shujun
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (09) : 3222 - 3234
12345